Urological Cancer 2021
López, José I. (editor)
Manini, Claudia (editor)
Cancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as well to this growth. Urological cancer is a complex and varied disease of different organs and mainly affects the male population. In fact, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males in most statistics. The female population, however, has also increasingly found itself affected by renal and bladder cancer in the last decade. Considering these altogether, urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light into the complexity of this field and will consider all useful and appropriate contributions that scientists and clinicians may provide to improve urological cancer knowledge for patients’ benefit. The precise identification of the molecular routes involved, the diagnostic pathological criteria in the grey zones, the dilemma of T1G3 management, and the possible treatment options between superficial, nonmuscle-invasive and muscle-invasive diseases will be particularly welcomed in this Issue.
Keywordsbladder cancer; radiotherapy; radiosensitisation; molecular subtypes; preclinical studies; bladder cancer cell lines; latent cancer; prostate cancer; autopsy; prognostic index; prediction model; mortality; screening trial; renal cell carcinoma; PD-1; PD-L1; biomarkers; immune checkpoint inhibitors; prostatic neoplasms; positron-emission tomography; decision making; tumor thrombus; metastasectomy; postoperative complications; oncological outcomes; radical cystectomy; AHNAK2; prognosis; dog; comparative oncology; inflammation; prostatic atrophy; preneoplastic lesion; biomarker; urine; machine learning; TRIPOD; liquid biopsy; glutaminase; immunohistochemistry; in situ methods; prostate; PSMA-RLT; 177Lu-PSMA; PSA; mCRPC; urinary bladder neoplasms; Bacillus Calmette–Guérin (BCG); immunotherapy; divergent differentiation; variant morphology; survival; stereotactic body radiotherapy; frail patients; cancer; metastasis; genomic analysis; microenvironment; tumor ecology; game theory; fluorescence confocal microscopy; prostate biopsy; ablation margins; focal therapy; sphingosine 1-phosphate receptor 1; bladder carcinoma; cell migration; epithelial–mesenchymal transition; FTY-720; OIP5; papillary renal cell carcinoma; PLK1; tumorigenesis; therapy; image-guided; magnetic resonance imaging; ultrasonography; biopsy; abiraterone; enzalutamide; docetaxel; novel hormonal therapies; comparative effectiveness; real-world treatment pattern; metastatic prostate cancer; epiplakin; diagnosis; advanced urothelial carcinoma; immune checkpoint inhibitor; prognostic; tumour mutational board; genomic signatures; ctDNA; inflammatory indices; urothelial carcinoma; frailty; prognostic factor; psoas muscle; Hounsfield units; n/a
Webshop linkhttps://mdpi.com/books/pdfview ...
Publication date and place2022
Research & information: general